ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO
Patients with Extended Treatment Benefit Showed an Objective Response Rate of 77.5% and a Median Duration of Response of 22.1 Months
Overall Adverse Event Profile Observed Consistent with Known Safety Profile of Mirvetuximab with Minimal Cumulative Toxicities
Study Outcomes in Patients with Long-Term Use Further Support Mirvetuximab’s Potential to Become New Standard of Care for FRα-positive Ovarian Cancer
"We believe the study outcomes presented at ESGO support the potential benefit mirvetuximab can have for a subset of patients on a long-term basis and add to the strong, existing foundation of data that supports mirvetuximab’s potential to become the new standard of care for FRα-positive ovarian cancer," said
CHARACTERIZATION OF EXTENDED TREATMENT BENEFIT FROM THREE PHASE 1 AND 3 CLINICAL TRIALS EXAMINING PATIENTS WITH FOLATE RECEPTOR ALPHA–POSITIVE RECURRENT OVARIAN CANCER TREATED WITH SINGLE-AGENT MIRVETUXIMAB SORAVTANSINE
A retrospective pooled analysis of patients who achieved ETB with mirvetuximab monotherapy was conducted across three studies - the Phase 1 IMGN853-0401 trial, the Phase 3 FORWARD I trial, and the Phase 3 SORAYA trial. ETB was defined as progression-free survival (PFS) for more than 12 months per investigator assessment. FRα expression levels were evaluated by immunohistochemistry (IHC).
In a pooled analysis of 466 patients, mirvetuximab monotherapy demonstrated ETB in 40 patients (9%).
- Most patients with ETB had stage III disease (83%), 1 prior line of therapy (55%), and prior Avastin® (bevacizumab) exposure (60%).
- EBT occurred in patients with a wide range of FRα expression, but did so predominantly among those with high FRα expression.
- Patients with ETB had an objective response rate (ORR) of 77.5% (31 out of 40 patients), with 10 (25%) achieving a complete response and 21 (52.5%) achieving a partial response. The remaining 8 patients (20%) with ETB had a best response of stable disease and one patient was not evaluable.
- Median duration of response (DOR) in patients with ETB was 22.1 months (95% CI, 13.8-60.0).
- Median PFS in patients with ETB was 17.0 months (95% CI, 16.4-23.1).
- In patients with ETB, the overall adverse event (AE) profile was consistent with the previously reported integrated safety summary (ISS) of 464 patients, with no new safety signals identified and minimal cumulative toxicities.
- AEs were primarily low-grade gastrointestinal and ocular events that generally resolved with supportive care or, if needed, dose modifications.
“Treatment options for patients with platinum-resistant ovarian cancer are extremely limited and characterized by low activity and considerable toxicity," said Ana Oaknin, Head of Gynecologic Tumors Unit,Vall d'Hebron Institute of Oncology, Senior Medical Oncologist and Attending Physician,
A trial in progress poster for a randomized Phase 2 investigator-sponsored trial (IST) of mirvetuximab in combination with carboplatin in patients with FRα-high recurrent ovarian cancer will also be presented.
Additional information can be found at www.congress.esgo.org.
ABOUT MIRVETUXIMAB SORAVTANSINE
Mirvetuximab soravtansine is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells.
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
Avastin® is a registered trademark of
This press release includes forward-looking statements. These statements include, but are not limited to, ImmunoGen's expectations related to: the occurrence, timing, and outcome of potential preclinical, clinical, and regulatory events related to, and the potential benefits of, the Company's product candidates, including, but not limited to, the review of the Company's BLA to the FDA for mirvetuximab and full approval of mirvetuximab, and the potential of mirvetuximab to serve as a new standard of care for patients with FRα-positive ovarian cancer; the timing and presentation of clinical data for the mirvetuximab program; and the Company's business and product development strategies. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of the Company's preclinical and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of preclinical studies, clinical trials, and regulatory processes; the Company's ability to financially support its product programs; the timing and outcome of the Company's anticipated interactions with regulatory authorities; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and the resulting impact on ImmunoGen's industry and business; and other factors as set forth in the Company's Annual Report on Form 10-K filed with the